#China #Beijing #Menarini Group #Bofanglutide #Gan & Lee

Strategic Partnership for Bofanglutide's European Market Entry

Gan & Lee Pharmaceuticals, a pioneering biopharmaceutical company, recently announced an exclusive partnership with Italy’s Menarini Group to facilitate the registration and commercialization of their novel obesity treatment, Bofanglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA). This collaboration signals a significant step towards expanding the accessibility of advanced therapeutics for obesity across Europe.

Partnership Overview

The agreement, officially disclosed on September 3, 2026, includes an initial payment of EUR 62 million to Gan & Lee, alongside milestone payments potentially reaching EUR 664 million, plus royalties from future sales. This transaction underscores the financial commitment and mutual interest in making effective weight management solutions available to a broader audience, particularly across the 39 targeted regions including all 27 EU member states, the UK, and several Nordic and Balkan countries.

Why Bofanglutide?

Bofanglutide, also known by its development code GZR18, is presented as a pivotal development in obesity management, administered bi-weekly. This innovative dosing schedule cuts the administration frequency in half compared to existing weekly GLP-1 RAs, making it more convenient for patients. Phase 3 trials in China and Phase 2 in the United States have already shown promising results in weight reduction and consistent safety profiles compared to other treatments in the same category.

Gan & Lee regards Bofanglutide as central to their strategy, aiming to leverage Menarini's established market presence and regulatory expertise to effectively launch the drug in highly regulated environments. With an extensive network in the pharmaceutical landscape, Menarini is poised to amplify Bofanglutide’s impact across Europe, enabling access to a vital resource for those struggling with obesity.

Rationale Behind the Collaboration

Elcin Barker Ergun, Group CEO of Menarini, emphasized the distinct advantages offered by Bofanglutide's once-every-two-weeks dosing. This differentiation, paired with results indicating efficacy and safety, positions the drug as a competitive option in the growing market for metabolic therapies. The partnership aims to carry out pivotal studies necessary for furthering approvals and bringing the medication to market, thereby providing alternatives to millions affected by obesity and related metabolic disorders.

Dr. Wei Chen, Chairman and CEO of Gan & Lee, expressed confidence in this collaboration, stating, "Our partnership represents a crucial entry point for our innovative products into Europe and showcases Gan & Lee's evolution from an insulin manufacturer to a leading developer in metabolic treatments. Our combined strengths in research, production, and regulatory strategies are set to enrich the therapeutic landscape in Europe."

Future Directions

Looking to the future, Gan & Lee is committed to a comprehensive global development strategy for Bofanglutide, planning to initiate a widespread Phase 3 clinical program in Europe. This will not only support registration but also aim to understand the broad applicability of Bofanglutide to diverse patient demographics. The company’s broader vision includes expanding its portfolio with innovative treatments across various therapeutic areas focusing on metabolic and cardiovascular diseases, bolstered by Meranini's robust commercial capabilities.

Conclusion

The alliance between Gan & Lee and Menarini marks a significant milestone for both companies, representing a leap toward modernizing treatment options for obesity. This partnership embodies a robust commitment to improving patient lives through innovative therapies, underscoring the urgent need for accessible solutions in preventing and managing obesity.

In conclusion, as both entities work together, the upcoming developments around Bofanglutide may revolutionize the treatment landscape for weight management, aligning with global health initiatives to combat obesity.